Traumatic Encephalopathy Syndrome and Tauopathy in a 19-Year-Old With Child Abuse.

PI-2620 cognitive decline physical child abuse tau PET tau protein traumatic encephalopathy syndrome

Journal

Neurotrauma reports
ISSN: 2689-288X
Titre abrégé: Neurotrauma Rep
Pays: United States
ID NLM: 101773091

Informations de publication

Date de publication:
2023
Historique:
medline: 29 12 2023
pubmed: 29 12 2023
entrez: 29 12 2023
Statut: epublish

Résumé

The majority of traumatic encephalopathy syndrome (TES) cases have been reported in former contact sport athletes. This is the first case with TES in a 19-year-old male patient with progressive cognitive decline after daily domestic physical violence through repeated hits to the head for 15 years. The patient presented with a moderate depressive episode and progressive cognitive decline. Tau positron emission tomography (PET) with 220 MBq of [

Identifiants

DOI: 10.1089/neur.2023.0078 PMID: 38156074 PMC: PMC10754342
pubmed: 38156074
doi: 10.1089/neur.2023.0078
pii: 10.1089/neur.2023.0078
pmc: PMC10754342
doi:

Types de publication

Journal Article

Langues

eng

Pagination

857-862

Informations de copyright

© Mike Rueb et al., 2023; Published by Mary Ann Liebert, Inc.

Déclaration de conflit d'intérêts

M.B. received speaker honoraria from GE healthcare, Roche, and LMI and is an advisor of LMI. H.Z. has served at scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). I.K. has served on the scientific advisory board for Abbott and is a stockholder of Siemens.

Auteurs

Mike Rueb (M)

Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany.
Pettenkofer School of Public Health, Munich, Germany.
Institute for Medical Information Processing, Biometry and Epidemiology, LMU University Hospital, LMU Munich, Munich, Germany.
Center for International Health (CIH LMU), LMU University Hospital, LMU Munich, Munich, Germany.

Katrin Rauen (K)

Department of Geriatric Psychiatry, Psychiatric Hospital Zurich, University of Zurich, Zurich, Switzerland.
Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Munich, Germany.

Inga Katharina Koerte (IK)

Psychiatric Neuroimaging Laboratory, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Child and Adolescent Psychiatry, Psychosomatic, and Psychotherapy, LMU University Hospital, Munich, Germany.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Alexandra Gersing (A)

Department of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, United Kingdom.
UK Dementia Research Institute, University College London, London, United Kingdom.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Joel Simrén (J)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Matthias Brendel (M)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE) Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Kristina Adorjan (K)

Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany.
Center for International Health (CIH LMU), LMU University Hospital, LMU Munich, Munich, Germany.
Institute of Psychiatric Phenomics and Genomics, LMU University Hospital, Munich, Germany.

Classifications MeSH